Please assess the completion status of the following clinical trial:

Trial Title: N-acetyl Cysteine Effect in Peripheral Neuropathy in Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients (\>18 years old).~2. Breast cancer patients who will receive adjuvant weekly paclitaxel for 12 cycles.~3. ECOG performance status 0-2~4. Adequate bone marrow function (white blood count ≥4,000/mm3, platelet count ≥100,000/mm3), liver function (serum total bilirubin \<1.5 mg/dl), renal function (creatinine \<1.5 mg/dl).~Exclusion Criteria:~1. Patients who have any of the following:~   * Clinical neuropathy.~  * Diabetes mellitus.~2. Patients receiving vitamin B1, B6, B12,or other vitamin supplemental therapy.~3. Patients receiving antidepressants, opioids, adjuvant analgesic agents (eg, anticonvulsants, clonazepam, or mexiletine), topical analgesics, and amifostine.~4. Hypersensitivity to NAC.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- control (Type: ACTIVE_COMPARATOR): they will receive paclitaxel 80 mg/m2 once per week for 12 weeks only
- high dose N-acetyl cysteine (Type: EXPERIMENTAL): they will receive paclitaxel 80 mg/m2 once per week for 12 weeks and high dose N-acetylcysteine (1200 mg twice daily) for the paclitaxel treatment period
- low dose N-acetyl cysteine (Type: EXPERIMENTAL): they will receive paclitaxel 80 mg/m2 once per week for 12 weeks and low dose N-acetylcysteine (600mg twice daily) for the paclitaxel treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).